Cargando…

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma

Malignant mesothelioma (MM) is a treatment-resistant tumor originating in the mesothelial lining of the pleura or the abdominal cavity with very limited treatment options. More effective therapeutic approaches are urgently needed to improve the poor prognosis of MM patients. Chimeric Antigen Recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castelletti, Laura, Yeo, Dannel, van Zandwijk, Nico, Rasko, John E. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885509/ https://www.ncbi.nlm.nih.gov/pubmed/33588928 http://dx.doi.org/10.1186/s40364-021-00264-1

Ejemplares similares

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
por: Reid, Glen, et al.
Publicado: (2020)

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
por: Klampatsa, Astero, et al.
Publicado: (2020)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways
por: Williams, Marissa, et al.
Publicado: (2019)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins αvβ3 and αvβ5
por: Cheng, Ngan Ching, et al.
Publicado: (2014)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

The next wave of cellular immunotherapies in pancreatic cancer
por: Yeo, Dannel, et al.
Publicado: (2022)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
por: Lin, Ruby C.Y., et al.
Publicado: (2016)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans
por: Wen, Lu, et al.
Publicado: (2022)

Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'
por: Kao, S C-H, et al.
Publicado: (2014)

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017)

Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
por: Masoumi, Elham, et al.
Publicado: (2020)

Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma
por: Fan, Xiyong, et al.
Publicado: (2019)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells
por: Yeo, Dannel, et al.
Publicado: (2022)

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
por: He, Xiaoqing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4ejvb8ie9vjg1da0gouri3d45v